Inogen (NASDAQ:INGN) Downgraded by StockNews.com to “Hold”

StockNews.com lowered shares of Inogen (NASDAQ:INGN) from a buy rating to a hold rating in a research note released on Wednesday.

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research report on Wednesday.

Inogen Trading Up 4.8 %

NASDAQ INGN opened at $8.33 on Wednesday. The business’s 50 day moving average is $10.18 and its two-hundred day moving average is $10.23. Inogen has a 12-month low of $6.14 and a 12-month high of $13.33. The stock has a market capitalization of $198.40 million, a price-to-earnings ratio of -3.70 and a beta of 1.02.

Hedge Funds Weigh In On Inogen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AlphaQuest LLC purchased a new stake in shares of Inogen during the 4th quarter worth approximately $43,000. Meeder Asset Management Inc. purchased a new stake in shares of Inogen during the 4th quarter worth approximately $56,000. Quarry LP purchased a new stake in shares of Inogen during the 3rd quarter worth approximately $59,000. Integrated Quantitative Investments LLC purchased a new stake in shares of Inogen during the 4th quarter worth approximately $92,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Inogen during the 4th quarter worth approximately $94,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.